Deep-tech and oncology lead India's startup funding week as Rekise and 4baseCare raise capital

Indian startups pulled in around $255 million across roughly 28 venture deals in the week of June 8 to 13, in a stretch marked less by consumer-internet plays than by science-led and strategically significant businesses. Two deals in particular captured the mood: marine-robotics firm Rekise Marine and precision-oncology startup 4baseCare, both of which secured fresh capital from prominent investors backing India's deep-tech and healthcare ambitions.

The composition of the week's funding, weighted toward early and growth-stage deals in defence-relevant technology, climate, and healthcare, reflects a broader shift in where capital is flowing. Investors increasingly favour startups building hard, defensible technology with clear strategic or enterprise demand over those chasing scale through subsidy-fuelled customer acquisition.

Rekise Marine and the defence-tech wave

Rekise Marine, which builds autonomous surface and underwater vessels, raised $9.7 million in a seed round led by Accel and NKSquared, the investment firm associated with entrepreneur Nikhil Kamath. Founded in 2017, the company develops robotic ships and submarines aimed at defence and commercial maritime applications, with its systems pitched toward use cases including naval operations and ocean security.

The deal sits squarely within a surge of investor interest in Indian defence and dual-use technology, a theme propelled by the government's push for self-reliance in critical systems. Backing an autonomous-maritime venture signals confidence that homegrown companies can supply sophisticated hardware once dominated by foreign suppliers, and that such capability carries both strategic and commercial value.

4baseCare and precision medicine

On the healthcare side, 4baseCare closed its Series B at Rs 128 crore, including a fresh top-up of Rs 38 crore led by growX Ventures and Infosys, with existing investors participating. Founded in 2019 by Hitesh Goswami and Kshitij Rishi, the company develops genomics-based cancer diagnostics and AI-powered clinical decision-support tools, aiming to make precision oncology more accessible and affordable in India and beyond.

The involvement of Infosys as a backer points to growing corporate interest in health-tech ventures that combine genomics with artificial intelligence. As cancer care moves toward personalised treatment guided by genetic profiling, companies that can deliver reliable diagnostics at scale stand to play a pivotal role in the healthcare system.

Where the capital is heading

Across the week, the pattern of deals pointed to several durable themes attracting venture money in India:

• Defence and dual-use deep tech, from robotics to autonomous systems
• Healthcare and life sciences, including genomics and AI-driven diagnostics
• Climate, energy and bioenergy ventures building physical infrastructure
• Enterprise tools and automation with immediate commercial demand

Industry trackers noted that the week comprised a healthy mix of growth-stage and early-stage rounds, a sign that capital is flowing across the funding lifecycle rather than concentrating only in late-stage bets. The breadth suggests an ecosystem maturing beyond its consumer-internet roots.

Outlook

With India having raised more than $8 billion across hundreds of equity rounds so far in 2026, the appetite for venture investment remains firmly intact. The emphasis on science-led and strategically significant startups suggests investors are positioning for a phase in which technological depth, rather than sheer scale, defines the winners. For founders building in deep tech and healthcare, the week offered a clear signal that capital is available for the right ideas.

The NE Times View

A week tilted toward marine-defence robotics and cancer diagnostics is healthier than another round of food-delivery clones. It suggests investors are finally rewarding hard science with long payoffs and strategic value. The caveat: deep-tech needs patient capital and procurement support, especially from the state in defence. One strong week is a signal, not a trend; sustained follow-on funding will tell us whether India's research-led ambitions have real legs.

This article is original commentary and analysis by The NE Times. Background facts were referenced from Entrackr, Business Standard and YourStory.